Nestle Health Science completed the acquisition of the remaining 74.4% stake in Aimmune Therapeutics for c. $2bn.

Nestle Health Science, a nutritional therapy company, completed the acquisition of the remaining 74.4% stake in Aimmune Therapeutics, a biopharmaceutical company, for c. $2bn. "The agreement with Nestlé Health Science recognizes the value created by years of commitment and dedication to our mission by the team at Aimmune. Delivering Palforzia, the world's first treatment for food allergy, has been a game-changing proposition in the bio-pharmaceutical industry and is transformative for the lives of millions of people living with potentially life-threatening peanut allergy. This acquisition ensures a level of support for Palforzia and our pipeline that will further enhance their potential for patients around the world living with food allergies," Jayson Dallas, Aimmune MD, President and CEO.